8 wyniki
This application is a 371 of PCT/EP97/03432. Filed Jul. 1, 1997.
The invention relates to 3-urea-pyridofurans and -pyridothiophenes, processes for their preparation and their use in medicaments.
It is known that the NADPH oxidase of phagocytes is the physiological source to the superoxide radical
BACKGROUND OF THE INVENTION
This invention relates to a new drug and a new technique for obtaining new curative effects from the drug.
Almost every internal disease of man is due to internal inflammations or injuries. They result from physical, chemical or biological agents. The latter ones are by
This invention relates to N-substituted-4-t-butyl-1-pyridinethiocarboxamides; which exhibit anti-inflammatory and non-narcotic analgesic activity. In particular, it relates to N-substituted-4-t-butyl-1,2,3,6-tetrahydro-pyridinethiocarboxamides, pharmaceutically acceptable salts thereof, their
The invention relates to heterocyclylcarbonyl substituted benzofuranyl-ureas, processes for their preparation and their use in medicaments.
It is known that the NADPH oxidase of phagocytes is the physiological source to the superoxide radical anion and reactive oxygen species derived therefrom which
The invention relates to N-(3-benzofuranyl)urea-derivatives, processes for their preparation and their use in medicaments.
It is known that the NADPH oxidase of phagocytes is the physiological source to the superoxide radical anion and reactive oxygen species derived therefrom which are important in
The invention relates to N-(3-benzofuranyl)urea-derivatives, processes for their preparation and their use in medicaments.
It is known that the NADPH oxidase of phagocytes is the physiological source to the superoxide radical anion and reactive oxygen species derived therefrom which are important in
INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ELECTRONICALLY
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Mar. 3, 2017, is named P12589-05_ST25.txt and
BACKGROUND OF THE INVENTION
Development of safe and effective agents for reducing the risk of cancer and other chronic diseases is a high priority of contemporary medicine. Implementation of strategies for chemoprevention/chemoprotection is beset with many problems.
In the economically developed